Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy

Table 2 Prevention of low-dose aspirin-induced gastroduodenal events

Ref.	Co-treatment	GI event	Incidence rate
Taha et al[17]	Famotidine 40 mg vs placebo	Gastric ulcers/duodenal ulcers	3.4% vs 15.0%
			0.5% vs 8.5%
Scheiman et al[18]	Esomeprazole 40 mg vs 20 mg vs placebo	Gastroduodenal ulcers	1.5% vs 1.1% vs 7.4%
Sugano et al[19]	Lansoprazole 15 mg vs placebo	Gastroduodenal ulcers	3.7% vs 31.7%
Yeomans et al[47]	Esomeprazole 20 mg vs placebo	Gastroduodenal ulcers	1.6% vs 5.4%
Ng et al[50]	Famotidine 40 mg vs pantoprazole 20 mg	Dyspeptic or bleeding ulcers/erosions	20% vs 0%
Chan et al[67]	Omeprazole 20 mg vs H. pylori eradication	Gastroduodenal bleeding	0.9% vs 1.9%
Lai et al[68]	H. pylori eradication + lansoprazole 15 mg vs H. pylori eradication	Gastroduodenal ulcers	1.6% vs 14.8%

GI: Gastrointestinal; H. pylori: Helicobacter pylori.